ADA: Sitagliptin Shows No Major Adverse CV Effects in T2DM, CVD

This article originally appeared here.
Share this content:
ADA: Sitagliptin Shows No Major Adverse CV Effects in T2DM, CVD
ADA: Sitagliptin Shows No Major Adverse CV Effects in T2DM, CVD

TUESDAY, June 9, 2015 (HealthDay News) -- For patients with diabetes and cardiovascular disease, the dipeptidyl peptidase 4 inhibitor sitagliptin does not appear to increase the risk of major adverse cardiovascular events, according to a study published online June 8 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 9 in Boston.

Jennifer B. Green, M.D., from the Duke University School of Medicine in Durham, N.C., and colleagues randomized 14,671 patients with type 2 diabetes and cardiovascular disease to add sitagliptin or placebo to their existing therapy. A relative risk of 1.3 was used as the marginal upper boundary to determine whether sitagliptin was noninferior to placebo.

The researchers observed a small difference in glycated hemoglobin levels during a median follow-up of 3.0 years. The primary outcome (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina) occurred in 11.4 percent of the sitagliptin group and 11.6 percent of the placebo group. For the primary outcome, sitagliptin was noninferior to placebo (hazard ratio, 0.98; 95 percent confidence interval, 0.88 to 1.09; P < 0.001).

"Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events," the authors write.

The study was funded by Merck Sharp & Dohme, the manufacturer of sitagliptin.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

Non-Nutritive Sweeteners Don't Up Blood Glucose Levels

Non-Nutritive Sweeteners Don't Up Blood Glucose Levels

Concentration of NNSs decreases gradually over the course of observation after consumption

Laws Allowing Service Denial to Sexual Minorities Tied to Distress

Laws Allowing Service Denial to Sexual Minorities Tied ...

Laws permitting denial of services linked to increase in mental distress among sexual minorities

Antidepressant Prescribing Linked to Lasting Weight Gain

Antidepressant Prescribing Linked to Lasting Weight Gain

Risk of weight gain remained increased during at least six years of follow-up